Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the deta…
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billio…
Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility…
Highlights: - Resource estimate completed for the Almaden Project with 910,000 ounces gold grading 0.65 g/t…
SolarWinds, ein führender Anbieter für erschwingliche IT-Management-Software, kündigt eine neue Version von SolarWinds…
New ProJet MJP 5600 multi-material composite 3D printer delivers new price performance standard for large format, mu…